Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 8, 2016, Pages 1099-1104

  Bollela, Valdes Roberto ^a   Namburete, E I ^a   Feliciano, C S ^a   Macheque, D ^b   Harrison, L H ^c   Caminero, J A ^d,e  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Nacional de Saú de Moçambique   (Mozambique)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

INH resistance; Line probe assay; Molecular diagnosis; Multidrug resistant tuberculosis; Mutations

Indexed keywords

ETHIONAMIDE; ISONIAZID; BACTERIAL PROTEIN; CATALASE; INHA PROTEIN, MYCOBACTERIUM; KATG PROTEIN, MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BRAZIL; CLINICAL DECISION MAKING; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIATION; GEOGRAPHICAL VARIATION (SPECIES); HEALTH CARE ACCESS; INHA GENE; KATG GENE; MOZAMBIQUE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PATIENT SELECTION; PREDICTIVE VALUE;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BRAZIL; CATALASE; CLINICAL DECISION-MAKING; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHIONAMIDE; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MOZAMBIQUE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84978301567     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.15.0864     Document Type: Article

References (37)

1. World Health Organization. Global tuberculosis control, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
2. Takayama K, Wang L, David HL. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1972; 2: 29-35.
3. Blanchard JS. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996; 65: 215-239.
4. Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: A systematic review. PLOS ONE 2015; 10: E0119628.
5. Scardigli A, Caminero JA. Management of drug-resistant tuberculosis. Curr Respir Care Rep 2013; 2: 208-217.
6. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int JTuberc Lung Dis 2009; 13: 1320-1330.
7. Müller B, Streicher EM, Hoek KG, et al. inhA promoter mutations: A gateway to extensively drug-resistant tuberculosis in South Africa? Int JTuberc Lung Dis 2011; 15: 344-351.
8. Baulard AR, Betts JC, Engohang-Ndong J, et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. JBiol Chem 2000; 275: 28326-28331.
9. Lee H, Cho SN, Bang HE, et al. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea. Int JTuberc Lung Dis 2000; 4: 441-447.
10. Moulding TS. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am Rev Respir Dis 1981; 123: 262-264.
11. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. Arandomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int JTuberc Lung Dis 2008; 12: 139-145.
12. World Health Organization. Molecular line-probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). Policy statement. Geneva, Switzerland: WHO, 2008. http://www.who.int/tb/features-Archive/policy-statement.pdf. Accessed August 2015.
13. Vijdea R, Stegger M, Sosnovskaja A, Andersen AB, Thomsen VO, Bang D. Multidrug-resistant tuberculosis: Rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur JClin Microbiol Infect Dis 2008; 27: 1079-1086.
14. World Health Organization. Noncommercial culture and drugsusceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis. Policy statement. WHO/HTM/TB/2011.9. Geneva, Switzerland: WHO, 2011.
15. Feliciano CS, Nascimento MM, Anselmo LM, Pocente RH, Bellissimo-Rodrigues F, Bollela VR. Role of a GenoType MTBDRplus line-probe assay in early detection of multidrugresistant tuberculosis at a Brazilian reference center. Braz JMed Biol Res 2015; 48: 759-764.
16. Torres JN, Paul LV, Rodwell TC, et al. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect 2015; 4: E42.
17. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrugresistant tuberculosis. Am JRespir Crit Care Med 2010; 182: 684-692.
18. Vadwai V, Ajbani K, Jose M, et al. Can inhA mutation predict ethionamide resistance? Int JTuberc Lung Dis 2013; 17: 129-130.
19. Telenti A, Honore N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: A blind study at reference laboratory level. JClin Microbiol 1997; 35: 719-723.
20. Van Rie A, Warren R, Mshanga I, et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. JClin Microbiol 2001; 39: 636-641.
21. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. JClin Microbiol 2007; 45: 2635-2640.
22. Santos LC, Bousquet Hde M, Pereira AM, Junqueira-Kipnis AP, Kipnis A. Ahigh prevalence of resistance in new tuberculosis cases of midwestern Brazil. Infect Genet Evol 2010; 10: 1052-1057.
23. Perizzolo PF, Dalla Costa ER, Ribeiro AW, et al. Characteristics of multidrug-resistant Mycobacterium tuberculosis in southern Brazil. Tuberculosis (Edinb) 2012; 92: 56-59.
24. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am JRespir Crit Care Med 2008; 177: 787-792.
25. Tolani MP, D'Souza DT, Mistry NF. Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India. BMC Infect Dis 2012; 12: 9.
26. Maurya AK, Singh AK, Kant S, et al. Use of GenoTypew MTBDRplus assay to assess drug resistance and mutation patterns of multidrug-resistant tuberculosis isolates in northern India. Indian JMed Microbiol 2013; 31: 230-236.
27. Singhal R, Myneedu VP, Arora J, et al. Early detection of multidrug resistance and common mutations in Mycobacterium tuberculosis isolates from Delhi using GenoType MTBDRplus assay. Indian JMed Microbiol 2015; 33 (Suppl): 46-52.
28. Li Z, Kelley C, Collins R, Rouse D, Morris S. Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. JInfect Dis 1998; 177: 1030-1035.
29. Ameeruddin NU, Hanna LE. Impact of isoniazid resistance on virulence of global and south Indian clinical isolates of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2014; 94: 557-563.
30. Kiepiela P, Bishop KS, Smith AN, Roux L, York DF. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from KwaZulu Natal, South Africa. Tubercle Lung Dis 2000; 80: 47-56.
31. Zhang Z, Lu J, Liu M, et al. Genotyping and molecular characteristics of multidrug-resistant Mycobacterium tuberculosis isolates from China. JInfect 2015; 70: 335-345.
32. Cavusoglu C, Turhan A, Akinci P, Soyler I. Evaluation of the GenoType MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. JClin Microbiol 2006; 44: 2338-2342.
33. Miotto P, Piana F, Penati V, Canducci F, Migliori GB, Cirillo DM. Use of GenoType MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. JClin Microbiol 2006; 44: 2485-2491.
34. Nikolayevskyy V, Balabanova Y, Simak T, Malomanova N, Fedorin I, Drobniewski F. Performance of the GenoType MTBDRplus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol 2009; 9: 2.
35. Schaaf HS, Victor TC, Venter A, et al. Ethionamide cross- And co-resistance in children with isoniazid-resistant tuberculosis. Int JTuberc Lung Dis 2009; 13: 1355-1359.
36. Ministério da Sa úde, Direçaõ Nacional de Assistência Medica. Guia de tratamento antirretroviral e infeç ões oportunistas no adulto adolescente: Gravida e criança. Maputo, Mozambique: MISAU, 2013. [Portuguese]
37. Brazil Ministério da Sa úde, Secretaria de Vigil ância em Sa úde, Departamento de Vigil ância Epidemiol ógica. Manual de recomendaç ões para o controle da tuberculose no Brasil. Brasília DF, Brazil: Ministério da Sa úde, 2011. [Portuguese]